Retatrutide, a experimental dual agonist of the GLP-1 receptor and glucose-dependent released polypeptide (GIP) target, is demonstrating promising results in early patient trials . Current examination https://socials360.com/story11990857/retatrutide-emerging-investigations-and-possible-therapeutic-applications